with NAFLD, and SIRT1 could be a therapeutic target of NAFLD.
Introduction
Nonalcoholic fatty liver disease (NAFLD) is a burgeoning health problem that begins with the aberrant accumulation of triglyceride in the liver. It includes isolated fatty liver and nonalcoholic steatohepatitis (NASH), the latter of which can progress to cirrhosis and liver cancer in some individuals (1) . Additionally, NAFLD is mostly common in obesity and metabolic syndrome, both of which are strongly associated with insulin resistance. What challenging us most is that there have been no drug therapy approved for NAFLD so far (2) .
Glucagon-like peptide-1 (GLP-1), an incretin hormone, is a gut-derived peptide secreted by intestinal L-cells after meal. It has pleiotropic functions in mammals as to promote insulin secretion of pancreatic β-cells, suppress inappropriate glucagon secretion, slow gastric emptying and induce insulin mediated glucose uptake (3) . As a new kind of anti-diabetic drugs, incretin mimetics, such as exenatide (exendin-4), have been proved by increasing amount of evidences that they could improve lipid deposition in liver effectively (4) (5) (6) . However, the specific mechanism underlying is little known. It was reported that GLP-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro (5) . A recent study found that exendin-4 could reduce inflammation in liver by inhibiting macrophage recruitment and activation (7) . Nevertheless, the exact mechanism as to signaling pathway of GLP-1 and its mimetics on improving hepatic steatosis is not fully understood. SIRT1, mammalian sirtuin 1, is a kind of NAD + -dependent protein deacetylase.
It is an important regulator of energy homeostasis in response to nutrient availability (8; 9) . We have previously found that loss of SIRT1 leads to more serious liver steatosis in SIRT1 +/-mice compared with wild-type (WT) mice after HFD induction (10) . Other study also showed that hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation (11) . On the other hand, hepatic over-expression of SIRT1 in mice attenuates endoplasmic reticulum stress and insulin resistance in the liver (12) . Activating SIRT1 signaling program by resveratrol or SRT1720 relieves fatty liver with reduced lipid synthesis and increased rate of fatty acid oxidation (13; 14) . A recent published study reported that SIRT1 mediated the activation of FGF21 which could prevent liver steatosis caused by fasting (15) . Another one demonstrated that hepatic deletion of SIRT1 promoted steatosis and inflammation in response to ethanol challenge via lipin-1, a transcriptional regulator of lipid metabolism (16) . All above indicate that SIRT1 is vital in the lipid homeostasis of liver.
Since SIRT1 plays such an essential role in the lipid metabolism of liver, whether GLP-1 receptor agonist exenatide ameliorating hepatic steatosis is mediated by SIRT1 remains to be investigated. Here, we presume that exenatide improves liver steatosis via SIRT1 pathway. In our study, SIRT1 +/-mice and their WT littermates were challenged with HFD following by exenatide treatment. We found that GLP-1 receptor agonist treatment could reverse liver steatosis in WT mice but not in SIRT1 +/-mice, which indicates that loss of SIRT1 significantly impairs the effect of GLP-1 receptor agonist. It is, for the first time to our knowledge, to point out that SIRT1
plays an indispensible role in mediating the effect of GLP-1 receptor agonist exenatide on ameliorating hepatic steatosis. (vol/vol) fetal bovine serum, 2mM L-glutamine, 1mM sodium pyruvate, 100 U/mL penicillin and 100mg/mL streptomycin at 37 °C in a humidified atmosphere containing 5% CO 2 . Cells were grown to 70% confluence and incubated in serum free Quantitative real-time PCR. Tissues were collected and kept in liquid nitrogen, then stored at -80℃. Total RNA was extracted from liver using TRIzol reagent (Invitrogen, Shanghai, China). RNA was reverse transcribed to cDNA using the Prime ScriptTM RT reagent kit (Takara, Japan). The primers were from the Applied Biosystems Statistical analysis. The data were presented as the mean ± SEM from multiple samples (n = 5-12 for each group in animal study). All of the in vitro experiments were replicated three times at least. Two-tailed, unpaired Student's t test was used in the statistical analysis with significance P ≤ 0.05. Both ip GTT and ip ITT were carried out after 8 weeks of exenatide administration.
Materials and Methods

Animals
Results
The
The fasting blood glucose (FBG) level of HFD challenged WT mice was higher than that on chow diet, and showed a significant reduction after exenatide treatment.
SIRT1
+/-mice had higher FBG compared with WT mice on HFD and this difference was sustained after exenatide treatment in two groups. But FBG level of SIRT1 +/-mice didn't show any statistical difference either with exenatide treatment or not ( Fig.   1E ). After administration of glucose, all trends above were maintained or even stronger at 30 mins and 60 mins (Fig. 1E) . Area under the curve (AUC) also revealed a significant improved glucose tolerance in WT mice after exenatide treatment.
However, the impaired glucose tolerance of SIRT1 +/-mice on HFD was not improved as much as that in WT mice after exenatide treatment (Fig. 1E ). During ip ITT test, administration of insulin led to a significant decrease of blood glucose levels in WT mice after exenatide treatment but not in SIRT1 +/-mice (Fig. 1F ). AUC showed statistical improved insulin sensitivity in WT mice after exenatide treatment. However, no statistical improvement of insulin sensitivity was observed in SIRT1 +/-mice on HFD after exenatide treatment (Fig. 1F ).
All above indicate that the effect of exenatide on reducing body weight and maintaining glucose homeostasis is attenuated in SIRT1 +/-mice.
Exenatide-improved liver weight, FBG and lipid profile are weakened in
SIRT1 +/-mice
After all of the treatments, we collected and weighed livers, detected FBG and fasting insulin level, and tested lipids profile in these mice. As expected, the liver weight in WT mice on HFD group was dramatically decreased after exenatide treatment compared with the saline control. However, this effect was weakened in SIRT1 +/-mice.
The same trend was observed in FBG change. Fasting insulin level didn't show significant difference among these groups due to big variation within groups (Table 1) .
Next, the lipids profile including triglyceride, glycerol, and total cholesterol in serum were tested. Exenatide treatment decreased the triglyceride, glycerol, and total cholesterol level by 37%, 29%, and 9% in HFD induced WT mice compared with the saline control, respectively (Table 1) . SIRT1 +/-mice had significantly higher lipids level in serum compared with WT mice on HFD, and this difference was sustained (Fig. 2B, X40 ). The white coloring and lipid droplets in hepatocytes were dramatically improved in HFD induced WT mice after exenatide treatment compared with the saline control; however, all these effects disappeared in SIRT1 +/-mice ( Fig. 2A-B) . Consistently, triglyceride, glycerol and total cholesterol contents in liver were decreased by 38%, 29%, and 13% in HFD induced WT mice with exenatide compared with the saline control, respectively. But no change was observed in lipid contents in HFD induced SIRT1 +/-mice after exenatide treatment ( Fig. 2C-E ).
SIRT1 is required by exenatide to alleviate inflammation in liver
As we know, activation of inflammatory processes was considered to be a consequence of fatty acids accumulation in liver (20) . Our previously research
showed that inflammatory genes expression were enhanced in liver of mice on HFD indicated by F4/80 and TNF-α gene expression (10) . Here, the results demonstrated (Fig. 3D) . The data suggest that SIRT1 is required by exenatide to relieve inflammation in liver. increased both SIRT1 and p-AMPK protein levels significantly in palmitate induced
HepG2 cells (Fig. 4E) . The phosphorylation of ACC, a substrate enzyme of AMPK, was up regulated in parallel with p-AMPK (Fig. 4E) . After silencing SIRT1 using SIRT1 RNAi, the effect of exendin-4 (20 nmol/L) was attenuated sharply (Fig. 4F ).
Resveratrol (50 µmol/L), a SIRT1 activator, was provided to compare with the effect of exendin-4 on palmitate induced HepG2 cells. As shown, the effect of exendin-4 on activating SIRT1 and p-AMPK was comparable with resveratrol ( Fig. 4G ).
Since SIRT1 is NAD + dependent, whether exendin-4 acts by altering the level of These data support our speculation that exenatide-reduced hepatic steatosis depends on SIRT1/AMPK pathway. (Fig. 5E) . Besides, Resveratrol (50 µmol/L) was provided to treat with palmitate challenged HepG2 cells. As shown, the effect of exendin-4 on inhibiting SREBP-1 was comparable with resveratrol (Fig. 5F ).
These results indicate that SIRT1 is required by exenatide to ameliorate lipogenesis via inhibiting SREBP-1 in liver.
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Discussion NAFLD has become a worldwide health concern since global incidence of obesity has increased. Epidemiological studies showed that NAFLD is strongly associated with T2DM-each is highly predictive of the other (24; 25). The coincident occurrence of hepatic steatosis and insulin resistance also leads to the hypothesis that excess triglyceride in liver causes insulin resistance which contributes to T2DM (2). Since ideal treatment for NAFLD has not been established, novel approaches aimed at reducing lipotoxicity and inhibiting proinflammatory are 
SIRT1 plays a vital role in hepatic lipid metabolism by deacetylation of acetylated lysine residues on histones and various transcriptional regulators (8).
Complete deletion of the SIRT1 gene leads to developmental defects and postnatal lethality (31; 32), which implies that SIRT1 -/-mice are not appropriate for the study for medication intervention. SIRT1 +/-mice are normal in development and postnatal growth (31; 32). As our animal experiments were proceeding, a study was reported that GLP-1 receptor agonist exendin-4 attenuated fatty liver through activation of
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SIRT1 in HFD induced C57BL/6J mice (19) . However, whether the effect of GLP-1 receptor agonist on improving fatty liver is mediated by SIRT1 has never been proved on genetically SIRT1 knockout model, and the exact mechanisms underlying remains elusive. Our data showed that hepatic steatosis, which was improved dramatically in WT group, diminished in SIRT1 +/-mice after exenatide treatment (Fig. 2B-D AMPK is a metabolic fuel gauge that regulates lipid metabolism through phosphorylation by sensing changes in the intracellular AMP/ATP ratio, especially in liver (21) . One recent study demonstrates that SIRT1 plays an essential role in the ability of moderate doses of resveratrol to stimulate AMPK and improve mitochondrial function (33) . SIRT1 also mediates the effect of alpha-lipoic acid on regulating lipid metabolism through activation of AMPK (34) . In the current study, we tested whether the actions of exenatide were mediated by SIRT1 through activation of AMPK. Our data showed that exenatide up regulated SIRT1 and p-AMPK in liver of HFD induced WT mice, but not in SIRT1 +/-mice ( Fig. 4A-C) . After silencing SIRT1 by lentivirus expressing SIRT1 RNAi in palmitate induced HepG2
Page 17 of 37 Diabetes cells, the effect of exendin-4 on increasing both SIRT1 and p-AMPK protein level was attenuated sharply as well (Fig. 4E-F) . The results support our speculation that exenatide's role in hepatic steatosis alleviation is mediated by SIRT1 through AMPK.
Hepatic steatosis could result from an increase of de novo lipogenesis. SREBP1c is one of the master lipogenic transcription factors of de novo lipogenesis in liver (22) . PNPLA3, a target gene of SREBP-1c, also plays a role in lipogenesis in mouse liver (23) . In our study, both SREBP-1 and PNPLA3 protein expression was decreased remarkably in HFD challenged WT mice after exenatide treatment, while no changes were observed in SIRT1 +/-mice with exenatide treatment (Fig. 5A-C) . In vitro, the effect of exendin-4 on inhibiting SREBP-1 was mediated by SIRT1 using RNAi method to knock down SIRT1 expression in palmitate induced HepG2 cells (Fig. 5E ). We also found that exendin-4 reduced the precursor of SREBP-1 (-P) 
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NAFLD includes isolated fatty liver and nonalcoholic steatohepatitis (NASH).
Hepatic steatosis is usually accompanied with chronic inflammation indicated by inflammatory cell infiltration during NAFLD progression according to liver histology findings (2) . A recent study finds that exendin-4 reduces inflammation in liver by reducing macrophage recruitment and activation (7) . In T2DM patients, administration of liraglutide, a GLP-1 analogue, improves liver inflammation and altered liver fibrosis (28) . Here in our study, inflammation was reduced by exenatide in liver of WT mice, and this effect disappeared in liver of SIRT1 +/-mice (Fig. 3) .
Recent studies have demonstrated SIRT1's properties in anti-inflammation (36) (37) (38) .
SIRT1 knockdown led to enhanced IκB kinase phosphorylation and NF-κB activation in adipocytes stimulated by lipopolysaccharide (LPS). It also resulted in increased expression of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 (36). In line with SIRT1's role of anti-inflammation, it's not hard to understand that SIRT1 is required by exenatide to alleviate inflammation in liver in our study, though the exact mechanism remains to be investigated further.
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Ex-4:exendin-4.
